Skip to main content

Table 2 mSASSS results for primary analysis set and for OASIS-Eligible patients

From: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Cohort Number Mean change ± SD from baseline to year 2 Pvaluea
Primary mSASSS analysis set
   OASIS 169 0.9 ± 3.3 0.771
   Adalimumab 307 0.8 ± 2.6  
OASIS-Eligible patients    
   OASIS 77 0.9 ± 4.1 0.744
   Adalimumab 307 0.8 ± 2.6  
  1. aP value calculated using analysis of covariance model with therapy as a factor and baseline modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) as a covariate. OASIS, Outcome in Ankylosing Spondylitis International Study; SD, standard deviation.